Skip to main content

Anthera Pharmaceuticals, Inc. (ANTH)

OTCMKTS: ANTH · Delayed Price · USD
0.0001 0.0000 (0.00%)
Dec 3, 2021 4:00 PM EST - Market closed
Market Cap2,618
Revenue (ttm)n/a
Net Income (ttm)-24.93M
Shares Out26.18M
EPS (ttm)-1.76
PE Ration/a
Forward PEn/a
Ex-Dividend Daten/a
Previous Close0.0001
Day's Range0.0001 - 0.0001
52-Week Range0.0001 - 0.1890
Price Targetn/a
Earnings Daten/a

About ANTH

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license ...

IPO DateMar 1, 2010
CEOJ. Craig Thompson
Stock ExchangeOTCMKTS
Ticker SymbolANTH
Full Company Profile

Financial Performance

Financial Statements


AM Best Assigns Issue Credit Ratings to Anthem, Inc.'s New Senior Unsecured Notes

OLDWICK, N.J.--(BUSINESS WIRE)--AM Best has assigned Long Term Issue Credit Ratings of “bbb+” to the newly issued senior unsecured notes of Anthem, Inc. (Anthem) (Indianapolis, IN) [NYSE:ANTH], which to...

8 months ago - Business Wire

AM Best Comments on Credit Ratings of Anthem, Inc. and Its Subsidiaries Following MMM Holdings, LLC Acquisition Annou...

OLDWICK, N.J.--(BUSINESS WIRE)--AM Best has commented that the Credit Ratings (ratings) of Anthem, Inc. (Anthem) (Indianapolis, IN) [NYSE: ANTH] and its insurance subsidiaries remain unchanged following...

10 months ago - Business Wire